Tamoxifen

Catalog No.S1238 Synonyms: ICI 46474

Tamoxifen Chemical Structure

Molecular Weight(MW): 371.51

Tamoxifen is an antagonist of the estrogen receptor in breast tissue.

Size Price Stock Quantity  
USD 147 In stock
USD 297 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

1 Customer Review

  • E, Analysis of BrCSC viability upon treatment with tamoxifen (tam) and fulvestrant (fulv) at the indicated doses. The experiments were performed in triplicates. ** P<0.01.

    Oncotarget, 2015, 6(4):2315-30.. Tamoxifen purchased from Selleck.

Purity & Quality Control

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Tamoxifen is an antagonist of the estrogen receptor in breast tissue.
Targets
estrogen receptor [1]
In vitro

TAM treatment inhibits significantly MCF7 cell proliferation. Low doses of TAM are able to induce structural chromosomal aberrations (deletions, isochromosomes, translocations, and dicentric chromosomes) in both ER+ and ER- breast cancer cells. This genotoxic effect is higher in those cell lines with HER2 gene amplification[2]. Whereas TAM at lower concentrations (0.1-1 μM) induces a cell-cycle arrest, pharmacological concentrations (above 5 μM) of TAM have been found to induce apoptosis of breast cancer cells. 5 μM TAM rapidly induced sustained activation of ERK1/2 in ER-positive breast cancer cell lines (MCF-7 and T47D)[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 cells NEPBOWlHfW6ldHnvckBie3OjeR?= NY\ZS4dQTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gZYdicW6|dDDNR2YuPyCkcnXhd5QhfHWvb4KgZ4VtdHNidYPpcochVUOILUegZZN{[XluIFXDOVA:OC5yMTFOwG0> MXGxNlgzPTl|NR?=
MCF7 cells MnroR5l1d3SxeHnjbZR6KGG|c3H5 NWnxZXZ3PDhiaB?= NIfmO4JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4xOjdizszN NWTKN3BkOjJ2N{KwOFU>
Ishikawa cells NHLLNHVHfW6ldHnvckBie3OjeR?= NWC3U|MyS2:wY3XueJJifGmxbjDv[kBkd22yb4Xu[EBz\XG3aYLl[EB1dyCrbnT1Z4UhPTBiJTDv[kB1cGVibXH4bY12dSC|dHnteYxifGmxbjDv[kBidGujbHnu[UBxcG:|cHjheIF{\SCjY4Tpeol1gSCrbjDJd4hqc2G5YTDj[YxteyxiRVO1NF0xNjB|MzFOwG0> NH\OPXk5OjBzNUi3
HEK293T cells MYDGeY5kfGmxbjDhd5NigQ>? M1\kVWFvfGGpb37pd5Qh[WO2aY\peJkh[XRiR3HsOEBFSkRvZoXz[YQhcHWvYX6gSXJidHCqYTDMRmQh\XiycnXzd4VlKGmwIFjFT|I6O1RiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBme3S{YXTpc4wucW6mdXPl[EB1emGwc3PybZB1cW:wYXygZYN1cX[jdHnvckBi\nSncjCyNEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCLQ{WwQVAvODN7IN88US=> M37kbVI{Pzh4NEWy
MDA-MB-435 cells MWHGeY5kfGmxbjDhd5NigQ>? NGfEZm5KdmirYnn0bY9vKG:oIF3ERU1OSi12M{WgZpJm[XO2IHPhcoNmeiClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OC5yNTFOwG0> M1PkTVE1QTdzOEm5
MDA-MB-231 cells MlHNSpVv[3Srb36gZZN{[Xl? NFzKV21KdmirYnn0bY9vKG:oIHXzeJJw\2WwIILlZ4VxfG:{IH7l[4F1cX[nIF3ERU1OSi1{M{GgZpJm[XO2IHPhcoNmeiClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:OC5yODFOwG0> MWexOFk4OTh7OR?=
T47D cells MX;GeY5kfGmxbjDhd5NigQ>? M{PR[GFvfGmnc4Tyc4dmdmmlIHHjeIl3cXS7IHnuJIh2dWGwIGS0O2Qh[2WubIOg[ZhxemW|c3nu[{Bme3S{b3flckBz\WOncITvdkBie3Onc4Pl[EBieyCnc4Tyc4dmdi2mZYDlcoRmdnRidILhcpNkemmydHnvckBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTB;MD6xJO69VQ>? NGTZSogyQTF|MUK0PC=>
Ishikawa cells MnPHSpVv[3Srb36gZZN{[Xl? NXjTdopuPzJiaB?= MYLBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDoeY1idiCLc3jpb4F4[SClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIV{fHKxZ3XuMYlv\HWlZXSgZYxs[WyrbnWgdIhwe3CqYYThd4Uh[WO2aY\peJkh[W[2ZYKgO|IhcHK|LDDJR|UxRTBwMUeg{txO NXyxRVdWOTh6M{WxO|Y>
MCF-7-2a cells MmjPSpVv[3Srb36gZZN{[Xl? MXLBcpRq\XO2cn;n[Y5q[yCjY4Tpeol1gSCrbjDNR2YuPy1{YTDj[YxteyCjczDjc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIILl[JVk\SCnc4TyZYRqd2xiZX\m[YN1KGK7IEWwKUwhUUN3ME2wMlUh|ryP M1Lrd|EzPDNzME[z
EL4 cell MnfGVJJwdGmoZYLheIlwdiCjc4PhfS=> NIO2ZWRKdmirYnn0bY9vKG:oIGuzTH11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDpcpRwKEWONDDj[YxtKHC{b3zp[oVz[XSrb36sJIlkPTB;MD61N|Uh|ryP NU\pToJCOTV5M{[zNC=>
HeLa cells MUfGeY5kfGmxbjDhd5NigQ>? NGn1TIJKdmirYnn0bY9vKG:oIEG3MYJmfGFvZYP0doFlcW:uIH3l[IlifGWmIHz1Z4ln\XKjc3WgeJJidnOlcnnweIlwdiCrbjDI[WxiKGOnbHzzJIV5eHKnc4PpcochcHWvYX6g[ZN1em:pZX6gdoVk\XC2b4KgZYxxcGF9IFXSSUBie3OjeTygTWM2OD1yLk[yNkDPxE1? NV\TUWNMOTV4NUi4OVE>
MDA-MB-231 cells NH;HbZVRem:uaX\ldoF1cW:wIHHzd4F6 Mn;yRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLk[2JO69VQ>? MVuyNFQ2OTN6MB?=
T47D cells NF\vWGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4HXSFczKGh? MoWxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6g[ZN1em:pZX6t[IVx\W6mZX70JHQ1P0RiY3XscJMh[W[2ZYKgO|IhcHK|LDDJR|UxRTFizszN NXHnOYpNOTlzM{GyOFg>
yeast AH109 cells NUHkV5NkTnWwY4Tpc44h[XO|YYm= NWnPO297OjRiaB?= MXjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEWUYnX0ZUBz\WOncITvdkBNSkRiZYjwdoV{e2WmIHnuJJlm[XO2IFHINVA6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gbY51\XKjY4Tpc44hf2m2aDDTVmMyKGGodHXyJFI1KGi{czDifUBidHCqYT3nZYxi[3Sxc3nkZZNmKGG|c3H5MEBKSzVyPUGuOlYh|ryP MmTyNlI3PDd{MUe=
GBM2 cells M2X5TnBzd2yrZnXyZZRqd25iYYPzZZk> NGezfVE4OiCq NXHTeWg3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0zKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:Oy53IN88US=> MVSyOlM2PTV|Mh?=
NCI-H460 cells NFrTXYdHfW6ldHnvckBie3OjeR?= M1rGR|I1KGh? M3;W[2FvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkAzPCCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVQvPDhizszN NYjZNWtpOTl5M{OwPFU>
GBM3 cells NXrnNY1xWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUe3NkBp M{TqRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVQvPyEQvF2= NX7P[2l1OjZ|NUW1N|I>
DLD1 cells Ml\DR5l1d3SxeHnjbZR6KGG|c3H5 MWG5OkBp MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEUGQyKGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;ND63PEDPxE1? M1zkOlIzPzR7M{my
ScN2a-cl3 cells M1\SR2N6fG:2b4jpZ4l1gSCjc4PhfS=> NYO4NIVxPSCmYYnz NXzDbZJmS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4Uh\Gm4aXTpcochW2OQMnGtZ4w{KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDjZYxk\WmwLVHNJJN1[WmwaX7nMYJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD12Lki5JO69VQ>? M{LzWlI1OTh|NUi5
K562 cells NWrsXGI5WHKxbHnm[ZJifGmxbjDhd5NigQ>? NVjmUFkxPzJiaB?= MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyPUWuNkDPxE1? NVr0UnExOjV2MkCxO|U>
MDA-MB-435S cells MYnDfZRwfG:6aXPpeJkh[XO|YYm= M2nLc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N|VUKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiSVO1NF02NjVizszN NHyxNVMzPjB5OUC5NC=>
DU145 cells NX33c4tjWHKxbHnm[ZJifGmxbjDhd5NigQ>? M16zbFQ5KGh? NGfpfplCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NT61JO69VQ>? M{PvUFI{Ojh5MEW3
HepG2 cells MXHQdo9tcW[ncnH0bY9vKGG|c3H5 NHP5UXQ1QCCq NXnzdWxrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[uN{DPxE1? NGm1eYkzOzJ6N{C1Oy=>
SKOV3 cells NV7X[HlHTnWwY4Tpc44h[XO|YYm= NIfzOVEzPCCq NXT3S4M4SW62aXPhcoNmeiCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z|IHPlcIx{KGGodHXyJFI1KGi{czDifUBUWkJiYYPzZZktKEmFNUC9Ok41KM7:TR?= Mn72NVk4OzNyOEW=
PC3 cells MUfQdo9tcW[ncnH0bY9vKGG|c3H5 NWnkWW9HOjRiaB?= NYDBOJlrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD15IN88US=> NFq1S24zPDh6MEKzNC=>
NIH/3T3 cells MmTHR5l1d3SxeHnjbZR6KGG|c3H5 NWOzeIZzQTZiaB?= M4C5bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9|VEOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF04NjJ4IN88US=> NV63RmYzOjJ5NEmzPVI>
GBM1 cells MXLQdo9tcW[ncnH0bY9vKGG|c3H5 NWXwZ3pUPzJiaB?= M13N[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVcvPSEQvF2= NIDQWI4zPjN3NUWzNi=>
518A2 cells M1rucmN6fG:2b4jpZ4l1gSCjc4PhfS=> NGfBd3Q6PiCq MmLTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gOVE5STJiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME23MlYzKM7:TR?= MUKyNlc1QTN7Mh?=
A2780 cells NYHzNHFMS3m2b4TvfIlkcXS7IHHzd4F6 MWC5OkBp NV;ncGNNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF04Njd5IN88US=> Mlf3NlI4PDl|OUK=
A549 cells NUnEdXNwS3m2b4TvfIlkcXS7IHHzd4F6 Ml;MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBjgSCPVGSgZZN{[XluIFnDOVA:QC52IN88US=> MnzkNlYxPzlyOUC=
Lipo cells NX\aZYZzS3m2b4TvfIlkcXS7IHHzd4F6 NIPLe5g6PiCq NEf3cVJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNcXCxIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9PE43PCEQvF2= MnPzNlI4PDl|OUK=
A253 cells NEP4S|NEgXSxdH;4bYNqfHliYYPzZZk> NUfuc2tMQTZiaB?= Moi1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI2OyClZXzsd{Bi\nSncjC5OkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUiuPVIh|ryP NFTze|QzOjd2OUO5Ni=>
HT-29 cells NU\CcW1XT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{nOOWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIx{NCCLQ{WwQVkvPSEQvF2= M4f2R|I{PDB|MEi0
LNCAP cells MofUVJJwdGmoZYLheIlwdiCjc4PhfS=> MWO0PEBp NXLpOZpPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{BmgHC{ZYPzbY5oKGGwZILv[4VvKHKnY3XweI9zKGmwY4XiZZRm\CC5aYToJFAvPiCwTTDv[kBme3S{YXTpc4wh[W6mIECuO{BvVSCxZjD0[ZN1d3O2ZYLvcoUh[W[2ZYKgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OTBizszN NU\y[ZdlOjF3MUOyO|U>
M21 cells MoXvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlfHS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUVIyKGOnbHzzMEBKSzVyPUGxJO69VQ>? M1PlOFI{PDB|MEi0
850C cells NIjEcZdEgXSxdH;4bYNqfHliYYPzZZk> NF\XSJQ6PiCq NVmybpRrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hQDVyQzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVEyNjB7IN88US=> Mnf2NlI4PDl|OUK=
HL60 cells NVrnNZp4S3m2b4TvfIlkcXS7IHHzd4F6 NIGxcXk4OiCq NX3FT|BiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhX1OWMTDhd5NigSCrbjDwdoV{\W6lZTDv[kAzOCViRlLTMEBKSzVyPUG0MlMh|ryP NHLnWVIzOjlyMUi5OS=>
MSTO-211H cells NUTiVGtTWHKxbHnm[ZJifGmxbjDhd5NigQ>? NXe2OG9SPzJiaB?= NVi5[IVmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNV3RQNTJzMVigZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHS{eYDhckBjdHWnIHHzd4F6NCCLQ{WwQVI{NjNizszN M1zG[FI{PzN3OEK5
HepG2 cells NWLTSFJVS3m2b4TvfIlkcXS7IHHzd4F6 MoraNlQhcA>? M3Oy[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFI1KGi{czDifUBE\WyuVHn0[ZIuSmy3ZVPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKzMlTPxE1? NV\Yb2RQOjB3NEWzN|Q>
KIF5 cells MmH1R5l1d3SxeHnjbZR6KGG|c3H5 MXuyOEBp MoXqWI95cWOrdImgZYdicW6|dDDoeY1idiCNSV[1JINmdGy|IHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KEOnbHzUbZRmeiCEbIXlJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI{Njd3IN88US=> M{PHeFIzPzd3NEe0

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT; 

PubMed: 30759864     


MCF-7 cells were treated with 2 μM tamoxifen and harvested at the indicated time point to analyze the expressions of p-AKT and AKT by western blot.

ER-α66 / ER-α36 / HER2 / EGFR; 

PubMed: 25203051     


Western blot analysis of the expression levels of ER-α66, ER-α36, HER2 and EGFR in ER-positive breast cancer MCF7 (A), T47D (B) and H3396 (C) cells treated with 1 µM of tamoxifen (TAM) for indicated time period.

p-AMPK / AMPK / p-ACC / ACC / p-P70S6K / p-S6 / p-4EBP1; 

PubMed: 27020861     


B. Immunoblot of AMPK pathway activation following treatment with 30μM tamoxifen in MCF7 and C. in MDA-MB-231 cells. 

CD36 / p-ERK / ERK ; 

PubMed: 30573731     


MCF-7 cells MCF-7 cells were treated with tamoxifen (Tam) at the indicated concentrations for 16 h, or with 5 μM Tam for the indicated times. Expression of CD36, p-ERK1/2 and ERK1/2 was determined by western blot.

30759864 25203051 27020861 30573731
Immunofluorescence
CD36; 

PubMed: 30573731     


MCF-7 cells were treated with tamoxifen (Tam) at the indicated concentrations for 16 h. Expression of CD36 was determined by immunofluorescent staining. 

30573731
In vivo Tamoxifen (TAM) is widely used for both treatment and prevention of breast cancer. However, it is also carcinogenic in human uterus and rat liver[2]. Tm-inducible Cre-loxP systems are being used in broad areas of research and are providing important biologic insights in tissue development, maintenance, and function. Tamoxifen-induced nuclear localization of Cre recombinase is time- and dose-dependent. Higher doses of tamoxifen induce recombination weeks following administration and Lower doses of tamoxifen induce recombination up to one week following administration. Duration of tamoxifen-induced gene recombination is also dose-dependent. Administration of high Tm doses leads to extended CreER nuclear localization. Tm treatment induces side effects that may have physiologic consequences in Tm-inducible models[4].

Protocol

Cell Research:

[2]

+ Expand
  • Cell lines: MCF7 and T47D
  • Concentrations: 10-6 mol/L
  • Incubation Time: 24, 48, and 96 h
  • Method:

    48 h before the addition of E2 and TAM, cells were washed with 5 mL phosphate-buffered saline (PBS) and then switched to phenol red-free RPMI-1640 containing 10% charcoal-stripped FBS. E2 and TAM were dissolved in absolute ethanol and diluted in the media at 10<sup>-8</sup> mol/L and 10<sup>-6</sup> mol/L, respectively, and then added to the culture medium at 24, 48, and 96 h.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Pdx1PB-CreERTm mice
  • Formulation: filter-sterilized corn oil
  • Dosages: --
  • Administration: s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 74 mg/mL (199.18 mM)
Ethanol 74 mg/mL (199.18 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.51
Formula

C26H29NO

CAS No. 10540-29-1
Storage powder
in solvent
Synonyms ICI 46474

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03879174 Not yet recruiting Breast Cancer Female Mediclinic Middle East August 1 2019 Phase 2
NCT03879174 Not yet recruiting Breast Cancer Female Mediclinic Middle East August 1 2019 Phase 2
NCT03879577 Not yet recruiting Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III University of Chicago April 10 2019 Phase 2
NCT03879577 Not yet recruiting Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III University of Chicago April 10 2019 Phase 2
NCT03870399 Recruiting Neuroendocrine Tumors|Progesterone Receptor Positive Tumor|Estrogen Receptor Positive Tumor AC Camargo Cancer Center March 13 2019 Phase 2
NCT03870399 Recruiting Neuroendocrine Tumors|Progesterone Receptor Positive Tumor|Estrogen Receptor Positive Tumor AC Camargo Cancer Center March 13 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me if you have a protocol for the use of tamoxifen (S1238) in vivo in mouse? Is there an administration way that is better than another?

  • Answer:

    Tamoxifen (S1238) can be dissolved in 10% ethanol/10% Tween 80/ddH2O at 5 mg/ml clearly. But precipitation will form if the formulation was left at RT for an hour or longer. So we'd suggest that you use it quickly after formulation. Tamoxifen is often administrated via i.p injection.

Estrogen/progestogen Receptor Signaling Pathway Map

Related Estrogen/progestogen Receptor Products0

Tags: buy Tamoxifen | Tamoxifen ic50 | Tamoxifen price | Tamoxifen cost | Tamoxifen solubility dmso | Tamoxifen purchase | Tamoxifen manufacturer | Tamoxifen research buy | Tamoxifen order | Tamoxifen mouse | Tamoxifen chemical structure | Tamoxifen mw | Tamoxifen molecular weight | Tamoxifen datasheet | Tamoxifen supplier | Tamoxifen in vitro | Tamoxifen cell line | Tamoxifen concentration | Tamoxifen nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID